PSNL · Personalis, Inc.

Personalis reported Q1 2026 results showing a strategic shift toward its core MRD offering, with total revenue declining to $15.5 million from $20.6 million year-over-year due to planned reductions in non-core segments like population sequencing and enterprise sales. Clinical revenue surged to $1.4 million from $0.3 million, fueled by 258% YoY growth in clinical test volume to 7,815 tests, up 26% sequentially, underscoring strong demand for the NeXT Personal test despite seasonal challenges. Pharma testing services contributed $11.2 million, while enterprise and population sequencing added $2.9 million. Gross costs rose to $15.2 million, but operating expenses escalated with R&D at $14.5 million and SG&A at $17.9 million, leading to an operating loss of $32.2 million and net loss of $30.0 million, or $(0.29) per share, versus $(0.18) last year. CEO Chris Hall emphasized the 'Win-in-MRD' strategy, highlighting Medicare coverage for lung cancer surveillance as a key milestone alongside breast cancer, positioning Personalis for reimbursement-driven growth. New product launches like Real-Time Variant Tracker and compelling clinical data presentations at AACR further validate the platform's ultrasensitivity. The company ended the quarter with a robust $233.2 million in cash, bolstered by $21.0 million from ATM sales. Reaffirmed full-year guidance projects total revenue of $78-80 million, with clinical revenue expanding five-fold to $10-11 million on 43,000-45,000 tests (171% YoY growth midpoint), pharma services at $55-56 million, and gross margins of 15-20% as volume ramps ahead of full reimbursement. Net loss outlook is $105 million with $100 million cash usage for commercial expansion, signaling confidence in scaling clinical adoption.